The roles of CEBPa mutations and its cooperating mutations in the relapse of acute myeloid leukemia (AML) are not clear. CEBPa mutations were analyzed on 149 patients with de novo AML at both diagnosis and relapse. Twenty-two patients (14.8%) had the mutations at diagnosis, two patients had N-terminal nonsense mutations alone, one had homozygous inframe duplication at the bZIP domain, and 19 patients had both N-terminal and bZIP mutations. Twenty patients relapsed with identical mutant patterns, two lost CEBPa mutations and none acquired the mutations at relapse. Cloning analysis showed that the N-terminal and C-terminal mutations occurred on separate cloned alleles and also on the same alleles in most of the diagnosis and relapse samples. Losing one of the two or more mutations on the same allele or acquiring the other mutation on the allele original carrying single mutation were observed not infrequently in the paired samples analyzed. Seven patients with CEBPa mutations had cooperating mutations with FLT3/ITD, FLT3/TKD or N-ras but not K-ras mutations. Our study showed that 91% of de novo AML harboring CEBPa mutations at diagnosis retained the identical mutant patterns but frequently changed in the allelic distribution at relapse.
Introduction
Transcription factor CCAAT/enhancer binding protein a (C/ EBPa) plays an important role in hematopoiesis and is essential for the differentiation of granulocytes.
1,2 CEBPa mutations have been described in 7-10% of adult patients with newly diagnosed acute myeloid leukemia (AML), [3] [4] [5] [6] [7] and were associated with a favorable prognosis. 5, 7 The role of CEBPa mutations in the progression of de novo AML is not clear. We have recently demonstrated that CEBPa mutations play a role in a subset of patients with myelodysplastic syndrome during the disease course; the patterns of CEBPa mutations in the progression to AML were heterogeneous, including retaining the identical mutant clones, loss of mutant clones or emergence of novel clones. 8 Up to now, only one study of CEBPa mutations in relapsed AML had been reported. 9 However, the patient number in that study was small, only two patients carried the mutations. Further study including a larger number of paired samples at both diagnosis and relapse from AML patients are required to define the role of CEBPa mutations in the relapse of AML.
In the present study, we analyzed CEBPa mutations in bone marrow (BM) samples collected at both diagnosis and relapse from 149 patients. We aimed to assess the role of the mutations in the relapse of AML and to determine whether the mutation pattern at relapse differed from those at initial diagnosis. In addition, the cooperating mutations with FLT3 and Ras genes in CEBPa mutation( þ ) patients were also analyzed. To the best of our knowledge, the present study is the largest series in which CEBPa mutations have been extensively analyzed in paired diagnostic and relapse samples.
Materials and methods

Samples
Between 1991 and 2004, BM samples from 132 adults and 17 children with de novo AML were examined at diagnosis and at first relapse. In addition, samples from 14 patients obtained at second relapse were also examined. Complete remission samples from patients who carried CEBPa mutations at diagnosis were also studied. Informed consent was obtained from each patient or the patient's guardians. This study was approved by the Human Research Committee of Chang Gung Memorial Hospital and Mackay Memorial Hospital. All relapse samples contained at least 20% BM blasts. The mononuclear cells from BM samples were enriched by Ficoll-Hypaque (1.077 g/ml, Amersham Pharmacia, Buckinghamshire, UK) density gradient centrifugation and cryopreserved in 10% dimethyl sulfoxide and 20% fetal bovine serum at À701C or in liquid nitrogen until use.
Cytochemical study, immunophenotyping, cytogenetic analysis, Southern blot analysis of MLL rearrangement, and reverse transcriptase-polymerase chain reaction (PCR) assay for detection of common fusion transcripts were performed on the diagnosis samples as described previously. 10 The morphologic subtypes were classified according to the French-AmericanBritish (FAB) criteria. 11, 12 Cytogenetic risk category was classified according to the criteria adopted by the UK Medical Research Council (MRC) AML10 trial, 13 with minor modification as follows: favorable risk group defined by the presence of t(8;21)/AML1-ETO, inv(16)/CBFb-MYH11, or t(15;17)/PMLRARa, irrespective of the presence of additional cytogenetic abnormalities; unfavorable risk group defined by the presence of À5/del(5q), À7/del(7q), 3q abnormalities, or complex karyotype X3 unrelated abnormalities; the remaining group of patients composed of the intermediate risk group except for patients with MLL rearrangements that were segregated as an additional group. Before 1995, adult patients received induction chemotherapy with daunomycin and cytarabine (3 þ 7) regimen followed by consolidation with (2 þ 5) regimen for three cycles and then weekly maintenance (6-thioguanine and cytarabine) and intensification therapy (cytarabine plus daunomycin or etoposide) every 3 months for 2 years. After 1995, the postremission therapy consisted of high-dose cytarabine plus daunomycin alternating with etoposide for 4-6 courses. Since 1994, patients with AML-M3 received all-trans-retinoic acid in addition to chemotherapy. Seventeen patients underwent stem cell transplantation. Pediatric patients were treated with TPOG-AML-901 and TPOG-AML-97 as described previously.
14 DNA PCR and direct sequencing for detection of CEBPa mutations DNA PCR assay followed by direct sequencing for each PCR product was performed as described previously. 8, 15 Briefly, the PCR reaction was carried out with two overlapping primer pairs PP1F and PP1R, and PP2F and PP2R which cover the entire coding region of human CEBPa.
3 PCR products were purified (Qiagen, Hilden, Germany) and sequenced using BigDye Terminators and AmpliTaq FS (ABI 3730, Applied Biosystems, Foster City, CA, USA) in both directions. Samples with abnormal or ambiguous sequencing results were subjected to repeated PCR assays with an alternative primer pairs. 8, 15 The PCR products were again purified and sequenced directly.
Expand long template PCR assay and cloning analysis
For samples carrying more than one mutant, expand long template PCR assay (Roche, Mannheim, Germany) using the primer pair of PP1F and PP2R was carried out to determine the allelic distribution of the multiple mutations on the same allele or on different alleles. The PCR product was subcloned into the pCRII-TOPO vector (Invitrogen, Carlsbad, CA, USA), and at least 10 clones were subsequently sequenced for each sample.
Detection of Ras and activating FLT3 mutations
The DNA PCR assay with direct sequencing for the detection of point mutations at codons 12, 13 and 61 of the N-ras gene, detection of internal tandem duplication of FLT3 (FLT3/ITD) and point mutations at tyrosine kinase domain of FLT3 (FLT3/TKD), GeneScan-based analysis of the FLT3/ITD mutant level, and sequencing of the duplicated fragments of FLT3/ITD were performed as previously described. 10, 16 For detection of K-ras mutations, the DNA or cDNA PCR assays were performed as those described for N-ras mutations except with the different primers as follows: for cDNA PCR assay, using the forward primers of K-ras-cF: 5 0 -CAT TTC GGA CTG GGA GCG AG-3 0 ; and the reverse primer of K-ras-cR: 5 0 -CTA TAA TGG TGA ATA TCT TCA AAT GAT TTA GT-3 0 which amplifying a fragment of 387 bps covering codons 12, 13 and 61. For DNA-PCR assay, (exon1) K-ras-E1-F was 5 0 -GGT GAG TTT GTA TTA AAA GGT ACT GGT G-3 0 and K-ras-E1-R was 5 0 -CCT CTA TTG TTG GAT CAT ATT CGT CC-3 0 ; (exon2) K-ras-E2-F was 5 0 -GGA TTC CTA CAG GAA GCA AGT AGT AA-3 0 and same K-ras-cR as for cDNA-PCR assay.
Statistical analysis
Frequencies of CEBPa mutations at diagnosis and relapse were compared with Fisher's exact test. w 2 analysis was used to compare data among different subgroups. The clinicohematologic variables and the presence of CEBPa mutations were compared by t-test. Overall survival was estimated by the method of Kaplan and Meier, and were compared using the logrank test. All P-values were calculated by using two-sided tests. Pp0.05 was considered as statistically significant. The statistic analysis was performed by using a software of SPSS 8.0 for Windows (SPSS Ins. Chicago, IL, USA).
Results
CEBPa mutations at diagnosis and at relapse
The paired diagnosis and relapse BM samples from 132 adult patients (ages ranged from 15 to 74 years with a median of 43 years; 72 were male) and 17 children (ages ranged from 5 months to 15 years with a median of 7.4 years, 13 were boys) were analyzed for CEBPa mutations. The first relapse occurred at a median of 9.4 months (range, 1.1-59.7 months) after the initial diagnosis. One hundred and twenty-seven patients had wildtype CEBPa at both diagnosis and relapse. CEBPa mutations were detected in 22 patients at diagnosis, two of them lost mutations and none acquired the mutation at relapse. As shown in Table 1 , 20 patients (nos. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] had mutations located in the N-terminal part of the protein resulting in frameshift and truncation of the proteins. Another one patient (no. 21) had a termination of translation by introducing a nonsense codon (P109X) and two additional outframe deletion at TAD2 and bZIP domains inducing a frameshift and termination. Nineteen patients (nos. 1-18 and 21) with N-terminal mutations also had C-terminal mutations at the bZIP domain, which consisted of inframe duplication, insertion, and deletion. Two patients (nos. 19 and 20) had N-terminal mutations alone; both had heterozygous single allelic mutations at N-part, patient 19 relapsed with an identical mutation whereas patient 20 lost Nterminal CEBPa mutation at relapse. The only one patient (no. 22) without N-terminal mutation had a homozygous C-terminal mutation with a large fragment of 66 bps (Q305-K326) duplication. We did not find any point mutation at bZIP domain. Together, 20 of the 22 patients harboring CEBPa mutations relapsed with identical mutation patterns, three of them had a second relapse that also exhibited the same patterns as their initial diagnosis and first relapse. None of the second relapse samples from 11 patients who lacked CEBPa mutations at diagnosis and first relapse acquired the mutations. CEBPa mutations were not detected in all complete remission samples obtained from the 22 patients who had mutations at diagnosis.
Cloning analysis of samples carrying more than one mutations
Samples harbored both N-terminal and bZIP mutations at diagnosis and relapse were all available for the expand long template PCR system followed by cloning analysis. The allelic frequency and distribution of combined N-terminal and Cterminal mutations of CEBPa of the 18 paired diagnosis and relapse samples are shown in Table 2 . At diagnosis, three patients (nos. 4, 9 and 10) had heterozygous biallelic mutations with N-terminal and bZIP mutations on the separate alleles, whereas the remaining 15 patients had at least one clone carrying combined mutations on the same allele apart from other clones harboring single mutations either at N-terminal or at bZIP domain. At relapse, three patients (nos. 1, 7 and 8) losing one of the two mutations on the same allele and two (nos. 9 and 10) acquiring the other mutation on the allele originally carrying single mutation. Patient 1 had combined mutations in most of the cloned alleles at diagnosis but relapsed with exclusively single mutation at bZIP domain in 15 of the 16 clones analyzed and the remaining one clone being wild-type. Patient 21 had three mutants at both diagnosis and relapse, cloning analysis showed a different allelic distribution between diagnosis and relapse samples (Table 3) ; four new cloned alleles were detected at relapse, with one clone carrying all three mutations on the same allele, and additional one each carrying N-terminal mutation plus mutation at TAD2 or bZIP domain, whereas the clone carrying 974_975 del alone was not observed in the 12 cloned alleles examined at relapse. Together, seven patients had changes in the alleleic distribution at relapse.
Cooperating mutations
Of the 22 patients with CEBPa mutations, two had concomitant FLT3/ITD mutations at diagnosis, one of them lost FLT3/ITD at relapse. Another two patients acquired FLT3/TKD mutations at relapse. N-ras mutations were detected in three patients with CEBPa mutations at diagnosis and two of them retained the identical N-ras mutations at relapse. None had K-ras mutations either at diagnosis or at relapse. Taken together, seven patients with CEBPa mutations at diagnosis/relapse had coexistence of FLT3/ITD, FLT3/TKD or N-ras mutations. Of the 127 patients without CEBPa mutations, FLT3/ITD, FLT3/TKD, N-ras and K-ras mutations were found in 27, 9, 14 and 4 patients, respectively. There was no difference in the frequency of cooperating 17 of them, only one patient with MLL-PTD had CEBPa mutation. The difference in the prevalence of CEBPa mutations among the cytogenetic/molecular subgroups at diagnosis was statistically significant (P ¼ 0.002).
The treatment outcome was analyzed according to the CEBPa mutation status at diagnosis. Kaplan-Meier analysis revealed that the median remission duration was 11.6 months for CEBPa mutation( þ ) patients and 9.0 months for CEBPa mutation(À) patients (P ¼ 0.142). The median overall survival was 22.6 months for patients with CEBPa mutations compared with 16.6 months for patients without CEBPa mutations (P ¼ 0.064).
Discussion
There has been only one small study including 26 patients with relapsed AML examined on CEBPa mutations, 9 in which only two patients had CEBPa mutations at diagnosis and both retained the mutations at relapse, none lost or acquired a mutation at relapse. In the present study, the incidence of CEBPa mutations in the cohort of AML patients who later had a relapse was 14.8% at initial diagnosis, 9.1% (2/22) of these patients lost the mutations and we did not observe the emergence of a novel mutation at relapse. We have recently described a heterogeneous pattern of CEBPa mutations, that is retaining the identical clones, clonal change or clonal evolution in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to AML. 8 Unlike the heterogeneous mutation pattern in myelodysplastic syndrome, we found that the vast majority of CEBPa mutant clones or subclones detected at diagnosis persisted at relapse in de novo AML. BM samples obtained at complete remission from all our 22 patients carrying CEBPa mutations at diagnosis did not harbor detectable CEBPa Table 2 Allelic frequency and distribution of combined mutations of CEBPa at diagnosis and at relapse in 18 patients 
The patient numbers 1-18 in this table are identical to those in Table 1 .
a No mutation present in the relapse sample. mutations, indicating that CEBPa mutations were leukemiaassociated and were essential for the leukemogenesis in those who had the mutations at both phases. The observation of CEBPa mutations being present only at diagnosis but not at relapse in our two patients suggested that chemotherapy might be able to eradicate the leukemic clones carrying the CEBPa mutations, and when the leukemia relapsed, the CEBPa mutant clones did not recur. For patients losing CEBPa mutations at relapse, it seems likely that other genetic alterations may be responsible for blocking CEBPa function. In the present study, two patients with CEBPa mutations had N-terminal mutations alone, one patient had only C-terminal mutation. Taken together, 86% (19/22) of our patients had both N-and C-terminal mutations of CEBPa, which were higher than the reported frequencies varying from 11% (1/9) to 40% (6/ 15). [3] [4] [5] 7 The discrepancy of the frequency of combined N-and C-terminal mutations between ours and previous studies might be attributed to the different patient population studied. We focused on relapsed AML patients and examined paired diagnosis and relapse samples whereas the previous studies focused only on diagnosis samples. All the CEBPa mutations detected in the present study were examined by repeated PCR with alternative primer pairs, which in conjunction with cloning analysis performed on all 19 paired samples carrying combined mutations; thus, at least three independent PCR assays reproducibly detected the presence of identical mutations in these patients. The very high frequency of combined N-terminal and bZIP domain mutations in our patients suggested that relapse was rarely detected in the subset of patients with only an N-terminal mutation. Leroy et al. 18 recently reviewed the 137 reported nonsilent CEBPa mutations in 87 patients with newly diagnosed AML, they divided the protein into five regions (R1-R5) with R1 and R4 accounting for 76% of the mutations. The distribution of the mutations in our patients were R1 68.2%, R2 27.3% and R4 90.9%. All but one mutation in R1 and R2 were 5 0 to the second ATG codon leading to the production of a truncated nonfunctional protein or overexpression of dominantnegative P30 isoform. Mutations at bZIP domain (R4) abrogate dimerization and DNA binding which in turn reducing the transactivation of CEBPa target genes. 3, 4 Cloning analysis demonstrated that the majority of the cloned alleles carried single N-terminal or C-terminal mutations on different alleles; but at least one clone harboring more than one mutation on the same alleles were detected in 79% (15/19) of diagnosis samples and 78% (14/18) of relapse samples. The allelic distribution of multiple CEBPa mutations in the initial diagnostic samples were also examined on diagnostic samples by two other groups, one described exclusively on different alleles 6 and the other observed a similar findings as ours with the presence of combined mutations on the same alleles or on different alleles. 7 It was interesting to note that changes in the allelic frequency and distribution occurred not infrequently at relapse in patients carrying combined mutations at diagnosis. As we only screened 10-32 clones for each sample in the cloning analysis, it was possible that the allelic frequency of CEBPa mutations might be different if much more clones would have been analyzed. Nevertheless, changes in allelic distribution of CEBPa mutations at relapse was not infrequent as compared with that at diagnosis. Lack of stability of CEBPa mutations in some cases of AML argued in favor of the mutations being a second event in leukemogenesis.
Two-hit hypothesis for the pathogenesis of AML has recently been proposed; one class of mutations that drive cell proliferation and survival and the other class of mutations that block differentiation. 19 Activating mutations of FLT3 or Ras genes lead to enhanced cellular proliferation and leukemic transformation, 20, 21 and CEBPa mutations result in the disruption of granulocyte differentiation. 22 Cooperating mutations with FLT3 and Ras genes were investigated on our patients with CEBPa mutations. Coexistence of FLT3/ITD, FLT3/TKD, or N-ras but not K-ras mutations were present in seven patients carrying CEBPa mutations at diagnosis and/or relapse. Our findings suggested that these genetic alterations played a role in the leukemogenesis through a collaborative manner in a subset of AML patients, which support the two-hit model of leukemogenesis. However, we failed to find a correlation between the frequency of cooperating mutations with FLT3/ITD, FLT3/TKD, N-ras or K-ras mutations and the mutation status of CEBPa.
We compared the clinicohematologic features of the population of relapsed AML according to the CEBPa mutation status. Most of CEBPa mutations were associated with AML-M1 or M2 morphology and intermediate risk cytogenetics as described previously in the newly diagnosed AML. [3] [4] [5] [6] [7] 23 CEBPa mutations were not observed in AML-M6 in the previous report, we did find one patient with M6 carrying the mutation. 11q23 abnormalities/MLL rearrangements have been assigned to either the unfavorable cytogenetic risk category or intermediate risk category by different study groups, 13, 24, 25 we thus segregated this genetic abnormalities to an additional subgroup. None of our patients with CEBPa mutations had favorable or unfavorable cytogenetic groups. CEBPa mutation was present in one patient with MLL-PTD and not detected in patients with other 11q23 translocations. As MLL-PTD is cytogenetically silent for 11q23 abnormality, there might have been cases with this genetic subtype in the reported cases classified as intermediate cytogenetics carrying CEBPa mutations. There was no difference in age, sex, blood counts, and percentage of blasts in BM or peripheral blood between patients with or without CEBPa mutations either at diagnosis or at relapse.
CEBPa mutations has recently been described to be associated with favorable outcome in adult AML with normal karyotypes. [5] [6] [7] The prognostic impact of CEBPa mutations was also analyzed in this selected cohort of relapsing AML patients. Patients with CEBPa mutations had a longer remission duration and overall survival than those without the mutations, but the difference did not reach statistical significance. However, the present study specially focused on a selected AML patients who ultimately relapsed, the survival data did not represent the real prognostic significance of CEBPa mutations in AML patients, that should include those who did not have relapses.
The detection of minimal residual disease is of growing importance in AML therapy. Almost all our AML patients with CEBPa mutations lacked other specific molecular markers. In addition, approximately 90% of CEBPa mutation( þ ) patients retained the identical mutants and none acquired a new mutant clone at relapse, therefore, CEBPa mutations might serve as a useful marker for monitoring of minimal residual disease or for detecting early relapse in these subset of patients except for those who lost CEBPa mutations at relapse. Although the majority of the N-terminal mutations included 1 bp deletion/ insertion, incorporating allele specific PCR using primers with sequences designed at mutation sites, into the real-time quantitative PCR assay would be able to measure the levels of CEBPa mutants for minimal residual disease monitoring.
